Litcius/Paper detail

Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis

Bernardo H. L. Goulart, Sirisha L. Mushti, Somak Chatterjee, Erin Larkins, Pallavi S. Mishra‐Kalyani, Richard Pazdur, Paul G. Kluetz, Harpreet Singh

2024The Lancet Oncology40 citationsDOI

Topics & Concepts

MedicineInternal medicineOncologyLung cancerChemotherapyProportional hazards modelImmunotherapyProgression-free survivalClinical trialCancerSurvival analysisRandomized controlled trialCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis | Litcius